Drug intelligence / Profile preview

QuickStripVax

Development stage: Preclinical
Lead developer: Rapid Dose Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Sublingual, Buccal

Overview

**QuickStripVax** is an orally dissolvable film technology platform developed by Rapid Dose Therapeutics for vaccine delivery, particularly explored for COVID-19 vaccines in collaboration with McMaster University and partners like Oakland Health Limited. It enables buccal or sublingual administration of vaccine proteins, addressing challenges in traditional vaccine delivery by offering a needle-free, stable format that dissolves rapidly in the mouth. Research has advanced ahead of schedule into next stages, demonstrating effective protein delivery through oral mucosa, with potential for broader vaccine applications beyond COVID-19.[9][15][16]

Brand names: QuickStripVax

Beyond the preview

Go deeper on QuickStripVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QuickStripVax.

Explore the full profile